SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is experiencing extreme volatility as the market reacts to the release of FDA briefing documents ahead of an upcoming advisory committee meeting. Investors are intensely debating the FDA's skepticism regarding clinical efficacy and statistical methodology, with community sentiment split between fear of a potential rejection and confidence that strong real-world data and patient testimony will ultimately lead to a positive outcome.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is facing intense volatility as investors speculate on potential downside ahead of a major insider share lock-up expiration in early August, which many fear will trigger a massive supply of shares hitting the market. While some long-term bulls point to institutional price targets and technical progress as reasons to accumulate, the community is heavily divided, with a vocal contingency of short sellers and skeptics betting on further price deterioration due to the company's high valuation and ongoing net losses.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following an agreement to expand its quantum computing partnership with AT&T, which will integrate D-Wave's technology into agentic AI systems to optimize network operations. The community is actively discussing the company's shift toward commercial enterprise deployment and potential long-term growth, though some traders remain cautious, noting that the stock's recent volatility reflects broader macro-driven profit-taking in high-beta tech.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp is seeing significant volatility as investors debate the impact of increased competition from Chinese chipmakers and broader uncertainty surrounding AI capital expenditure sustainability. The community remains deeply divided, with some traders aggressively shorting the stock amid technical breakdowns while others advocate for long-term accumulation, viewing the recent sharp pullbacks as buying opportunities before upcoming earnings.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing and the broader quantum sector are trending following executive orders from the Trump administration aimed at accelerating U.S. quantum technology leadership and secure data migration, sparking intense community debate over government funding versus high valuation concerns. While some investors are bullish on the policy support and new commercial testbed partnerships like TangleLab, others caution against speculative hype, highlighting high cash burn rates and concerns that recent price rallies are detached from enterprise revenue milestones.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is drawing significant market attention following a massive $500 billion partnership with SK Group to secure next-generation memory supply and data center infrastructure, alongside discussions to backstop large-scale OpenAI data center financing. Investors are actively debating the sustainability of this aggressive infrastructure spending cycle, weighing the company's long-term enterprise demand against concerns regarding financing structures and potential market saturation.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors react to the company's decision to accelerate the lockup expiration for restricted shares, triggering intense debate over the fund's current valuation relative to its NAV. The community remains deeply divided, with bulls pointing to the fund's exposure to high-profile AI companies like Anthropic and OpenAI, while bears warn of extreme overvaluation and the potential for a significant sell-off once locked shares hit the market.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is trending following a significant leadership transition, with investors closely watching the appointment of an interim CEO as the company navigates competitive pressure in the multiple myeloma space. Community discussion is heavily focused on the potential for a buyout, with many viewing the current share price weakness as an entry opportunity given the strong commercial performance of Carvykti and the company's emerging in-vivo pipeline.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is experiencing significant volatility and aggressive price swings as investors navigate broader tech sector de-risking and sector-wide rotations. The community remains focused on strong long-term fundamentals, with many viewing recent pullbacks as buying opportunities fueled by anticipation of sustained AI hyperscaler capital expenditure.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors weigh strong U.S. commercial potential against recent volatility, fueled by the upcoming CHMP opinion on Yartemlea and a strategic buyback of convertible notes. Community discussion remains polarized between bullish sentiment regarding the drug's FDA-approved status and competitive positioning versus concerns over transparency, pipeline execution, and the departure of key executives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2036 Corporate Bond ETF

Neutral Sentiment

U.S. - Iran negotiations

Earnings

FOMC meeting

Other (drop a comment)

This week brings a Federal Reserve rate decision, Q2 GDP and PCE inflation data, and earnings from $MSFT, $META, $AAPL, and $AMZN. What will be the biggest driver of the market this week? Vote and explain your reasoning in the comments.

What will be the main driver of the market this week? 
 
Explain your reasoning in the comments.

Current Price	$19.69
Prev Close	$19.68
Open	$19.71
Dividend Yield	N/A
50-Day Moving Average	$20.09
Beta	N/A
Avg. Volume	11,918.54
PE Ratio	N/A

52-Week High	$20.33
52-Week Low	$19.66
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

BSCAInvesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2036 Corporate Bond ETF

Latest BSCA News